Ironwood Pharmaceuticals Insider Buys 63,481 Shares

Jon Duane, an insider at Ironwood Pharmaceuticals, Inc. (NasdaqGS: IRWD), purchased 63,481 shares of the company on June 16, 2026. The transaction was not part of a prearranged plan and comes as the stock trades around $3.66.

Insider Buying and Selling at Ironwood Pharmaceuticals, Inc.

Several insiders, including Jon Duane, Shepard Jay, Marla Kessler, Alexander Denner, Catherine Moukheibir, and Julie McHugh, each bought 63,481 shares of Ironwood Pharmaceuticals on June 16, 2026. These purchases were not under Rule 10b5-1 plans.

Other Institutional Activity in Ironwood Pharmaceuticals

Institutional investors have been active in Ironwood Pharmaceuticals. Armistice Capital, LLC reduced its holdings by 997,000 shares to 15,028,000 shares, valued at approximately $52.7 million. BlackRock, Inc. increased its position by 578,124 shares, bringing its total to 13,362,930 shares worth about $46.9 million. Sarissa Capital Management LP significantly reduced its stake by 6,730,800 shares, leaving it with 9,188,635 shares valued at $32.3 million. AQR Capital Management LLC notably increased its holdings by 2,811,549 shares, resulting in a total of 7,535,080 shares valued at $26.4 million.

Ironwood Pharmaceuticals Stock Snapshot

Shares of Ironwood Pharmaceuticals, Inc. (NasdaqGS: IRWD) are trading close to $3.66. The company boasts a market cap of approximately $579.4 million. It has a P/E ratio of 5.68 and a forward P/E of 2.44, indicating relatively low valuation multiples. Its beta of 0.241 suggests lower volatility compared to the market. The stock's 52-week range spans from $0.66 to $5.78, with a 50-day moving average of $3.86 and a 200-day moving average of $3.25.

Recent Earnings

In its latest earnings report, Ironwood Pharmaceuticals posted revenue of $361.5 million, reflecting a growth rate of 1.59%. The company achieved a net margin of 28.26% and an EPS of $0.62. Investors are looking forward to the next earnings announcement on August 6, 2026.

Analysts Set New Price Targets

On February 26, 2026, Citizens maintained its buy rating on Ironwood Pharmaceuticals with a price target of $10. Meanwhile, Wells Fargo has maintained a hold rating with a target price of $5 as of January 5, 2026. The consensus among analysts is a moderate buy, with a mean target price of $6.10 based on four analyst opinions.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc. is a biotechnology company headquartered in Boston, Massachusetts. It focuses on developing and commercializing therapies for gastrointestinal and rare diseases. The company markets linaclotide, a treatment for irritable bowel syndrome with constipation, under the LINZESS and CONSTELLA brands. Ironwood is also developing treatments for visceral pain conditions and short bowel syndrome. The company collaborates with partners like AbbVie, AstraZeneca, and Astellas Pharma for its linaclotide product.

Bottom Line

Ironwood Pharmaceuticals has seen insider buying activity, with multiple insiders purchasing shares on June 16, 2026. The stock, trading around $3.66, offers a glimpse into the company's valuation and recent institutional moves. While analysts have varied views, the consensus leans towards a buy, reflecting optimism about Ironwood's future prospects. Keep in mind, insider transactions and institutional filings are historical and may not indicate current positions.